Advertisement

Journal of Neurology

, Volume 266, Issue 5, pp 1260–1266 | Cite as

Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

  • Adam P. VogelEmail author
  • Lisa H. Stoll
  • Andreas Oettinger
  • Natalie Rommel
  • Eva-Maria Kraus
  • Dagmar Timmann
  • Dion Scott
  • Christina Atay
  • Elsdon Storey
  • Ludger Schöls
  • Matthis Synofzik
Original Communication

Abstract

We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

Keywords

Speech Dysarthria Rehabilitation Acoustics Ataxic neuropathy Voice 

Notes

Acknowledgements

This study was supported by the Ataxia Charlevoix-Saguenay Foundation and from the European Union’s Horizon 2020 research and innovation program under the ERA-NET Cofund action N° 643578. It was supported by the BMBF (01GM1607 to M.S.), under the frame of the E-Rare-3 network PREPARE (to M.S.). A.P.V. received salaried support from the National Health and Medical Research Council, Australia (Career Development Fellowship ID 1082910), and received funding from the Alexander von Humboldt Foundation. This study was supported by the IZKF Promotionskolleg Tübingen (IZKF 2016-1-07) to M.S. and E.K.

Author contributions

AV designed the treatment and contributed to the design of the study, collection, analysis and interpretation of the data, and drafting the manuscript. He also supervised students, led the research team, and obtained funding for the research. LS contributed to data analysis and interpretation and revising the manuscript for intellectual content. AO contributed to data analysis and interpretation and revising the manuscript for intellectual content. E-MK contributed to data analysis and interpretation and revising the manuscript for intellectual content. DS contributed to therapy material preparation and revising the manuscript for intellectual content. CA contributed to therapy material preparation and revising the manuscript for intellectual content. NR contributed to the design of the study, collected data, analysis and interpretation of the data, revising the manuscript for intellectual content, and supervision of students. LS, DT and ES contributed to data interpretation and revising the manuscript for intellectual content. MS contributed to the design of the study, collection, analysis and interpretation of the data, and revising the manuscript for intellectual content. He also supervised students, led the research team, and obtained funding for the research.

Compliance with ethical standards

Conflicts of interest

All authors declare that they have no conflict of interest.

Ethical standards

The study received institutional ethical approval (The University of Melbourne 1339394.2, University Hospital Tübingen, Germany Az. 003/2015BO2). The trial was registered with ID ACTRN12616001583437 (anzctr.org.au).

Supplementary material

415_2019_9258_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 KB)

Supplementary material 2 (MOV 150740 KB)

References

  1. 1.
    Ballard KJ, Robin DD, McCabe P, McDonald J (2010) A Treatment for dysprosody in childhood apraxia of speech. J SpeechGoogle Scholar
  2. 2.
    Constantinescu G, Theodoros D, Russell T, Ward EC, Wilson SM, Wootton R (2011) Treating disordered speech and voice in Parkinson’s disease online: a randomized controlled non-inferiority trial. Int J Lang Commun Disorders 46:1–16Google Scholar
  3. 3.
    Hargrove PM (2013) Pursuing prosody interventions. Clin Linguist Phonet 27:647–660CrossRefGoogle Scholar
  4. 4.
    Katz S (1983) Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31:721–727CrossRefGoogle Scholar
  5. 5.
    Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRefGoogle Scholar
  6. 6.
    Park S, Theodoros DG, Finch E, Cardell E (2016) Be clear: a new intensive speech treatment for adults with nonprogressive dysarthria. Am J Speech-Lang Pathol 25:97–110CrossRefGoogle Scholar
  7. 7.
    Schiavetti N, Metz DE, Sitler RW (1981) Construct validity of direct magnitude estimation and interval scaling of speech intelligibilityevidence from a study of the hearing impaired. J Speech LangHear Res 24:441–445CrossRefGoogle Scholar
  8. 8.
    Schmitz-Hubsch T, Du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang J-S, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, Van De Warrenburg BP, Durr A, Klockgether T (2006) Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology 66:1717–1720CrossRefGoogle Scholar
  9. 9.
    Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, Haack TB, Schöning M, Biskup S, Rudnik-Schöneborn S, Senderek J, Hoffmann KT, MacLeod P, Schwarz J, Bender B, Krüger S, Kreuz F, Bauer P, Schöls L (2013) Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Diseases 8:41CrossRefGoogle Scholar
  10. 10.
    Tamplin J (2008) A pilot study into the effect of vocal exercises and singing on dysarthric speech. Neuro Rehabil 23:207–216Google Scholar
  11. 11.
    Tjaden K, Sussman JE, Wilding GE (2014) Impact of clear, loud, and slow speech on scaled intelligibility and speech severity in parkinson’s disease and multiple sclerosis. J Speech Lang Hear Res 57:779–792CrossRefGoogle Scholar
  12. 12.
    Vogel AP, Fletcher J, Snyder PJ, Fredrickson A, Maruff P (2011) Reliability, stability, and sensitivity to change and impairment in acoustic measures of timing and frequency. J Voice 25:137–149CrossRefGoogle Scholar
  13. 13.
    Vogel AP, Folker JE, Poole ML (2014) Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. Cochrane Database Syst Rev 10Google Scholar
  14. 14.
    Vogel AP, Rommel N, Oettinger A, Horger M, Krumm P, Kraus E-M, Schöls L, Synofzik M (2017) Speech and swallowing abnormalities in adults with POLG associated ataxia (POLG-A). Mitochondrion 37:1–7CrossRefGoogle Scholar
  15. 15.
    Vogel AP, Rommel N, Oettinger A, Stoll LH, Kraus E-M, Gagnon C, Horger M, Krumm P, Timmann D, Storey E, Schöls L, Synofzik M (2018) Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS). J Neurol 265:2060–2070CrossRefGoogle Scholar
  16. 16.
    Weismer G, Laures JS (2002) Direct magnitude estimates of speech intelligibility in dysarthria: effects of a chosen standard. J Speech Lang Hear Res 45:421–433CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Adam P. Vogel
    • 1
    • 2
    • 3
    Email author
  • Lisa H. Stoll
    • 1
    • 4
  • Andreas Oettinger
    • 5
  • Natalie Rommel
    • 1
    • 4
  • Eva-Maria Kraus
    • 1
  • Dagmar Timmann
    • 6
  • Dion Scott
    • 7
  • Christina Atay
    • 7
  • Elsdon Storey
    • 8
  • Ludger Schöls
    • 1
    • 9
  • Matthis Synofzik
    • 1
    • 9
  1. 1.Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for NeurologyUniversity of Tübingen, University Hospital TübingenTübingenGermany
  2. 2.Centre for Neuroscience of SpeechThe University of MelbourneMelbourneAustralia
  3. 3.RedenLabMelbourneAustralia
  4. 4.Therapiezentrum, University Hospital TübingenTübingenGermany
  5. 5.Neurology and RehabilitationKliniken SchmiederGailingen am HochrheinGermany
  6. 6.Department of Neurology, Essen University HospitalUniversity of Duisburg-EssenEssenGermany
  7. 7.The University of QueenslandSt LuciaAustralia
  8. 8.Department of MedicineMonash UniversityMelbourneAustralia
  9. 9.Center for Neurodegenerative Diseases (DZNE)TübingenGermany

Personalised recommendations